439 related articles for article (PubMed ID: 22629545)
41. Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases.
Aukema TS; Valdés Olmos RA; Wouters MW; Klop WM; Kroon BB; Vogel WV; Nieweg OE
Ann Surg Oncol; 2010 Oct; 17(10):2773-8. PubMed ID: 20422454
[TBL] [Abstract][Full Text] [Related]
42. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
43. 18F-FDG PET-CT as a supplement to CT/MRI for detection of nodal metastasis in hypopharyngeal SCC with palpably negative neck.
Lee HJ; Kim J; Woo HY; Kang WJ; Lee JH; Koh YW
Laryngoscope; 2015 Jul; 125(7):1607-12. PubMed ID: 25643834
[TBL] [Abstract][Full Text] [Related]
44. Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.
Povoski SP; Hall NC; Murrey DA; Wright CL; Martin EW
BMC Cancer; 2015 May; 15():378. PubMed ID: 25953144
[TBL] [Abstract][Full Text] [Related]
45. Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary.
Freudenberg LS; Fischer M; Antoch G; Jentzen W; Gutzeit A; Rosenbaum SJ; Bockisch A; Egelhof T
Med Princ Pract; 2005; 14(3):155-60. PubMed ID: 15863988
[TBL] [Abstract][Full Text] [Related]
46. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
47. [FDG PET/CT versus PET alone for pre-surgical detection of lymph node metastasis in esophageal carcinoma].
Yuan SH; Yu JM; Yu YH; Fu Z; Guo HB; Liu TH; Yang XH; Yang GR; Li WW
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):221-4. PubMed ID: 17649642
[TBL] [Abstract][Full Text] [Related]
48. [F-18 FDG PET for detection of occult primary tumor in patients with lymphatic metastases of the neck region].
Bohuslavizki KH; Klutmann S; Sonnemann U; Thoms J; Kröger S; Werner JA; Mester J; Clausen M
Laryngorhinootologie; 1999 Aug; 78(8):445-9. PubMed ID: 10488465
[TBL] [Abstract][Full Text] [Related]
49. The real additional value of FDG-PET in detecting the occult primary tumour in patients with cervical lymph node metastases of unknown primary tumour.
de Bree R
Eur Arch Otorhinolaryngol; 2010 Nov; 267(11):1653-5. PubMed ID: 20827553
[No Abstract] [Full Text] [Related]
50. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic value of only 18F-fluorodeocyglucose positron emission tomography/computed tomography-positive lymph nodes in head and neck squamous cell carcinoma.
Lee SH; Huh SH; Jin SM; Rho YS; Yoon DY; Park CH
Otolaryngol Head Neck Surg; 2012 Oct; 147(4):692-8. PubMed ID: 22535915
[TBL] [Abstract][Full Text] [Related]
52. The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor.
Fogarty GB; Peters LJ; Stewart J; Scott C; Rischin D; Hicks RJ
Head Neck; 2003 Feb; 25(2):138-45. PubMed ID: 12509797
[TBL] [Abstract][Full Text] [Related]
53. In search of an unknown primary tumour presenting with extracervical metastases: the diagnostic performance of FDG-PET.
Joshi U; van der Hoeven JJ; Comans EF; Herder GJ; Teule GJ; Hoekstra OS
Br J Radiol; 2004 Dec; 77(924):1000-6. PubMed ID: 15569641
[TBL] [Abstract][Full Text] [Related]
54. Utility of quantitative 18 F-fluorodeoxyglucose uptake measurement to identify occult tonsillar carcinoma in patients with cervical metastasis of unknown primary tumours: a retrospective case-control study.
Lee HJ; Kim JS; Roh JL; Lee JH; Cho KJ; Park GC; Choi SH; Nam SY; Kim SY
Clin Otolaryngol; 2013 Feb; 38(1):30-8. PubMed ID: 23167514
[TBL] [Abstract][Full Text] [Related]
55. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
[TBL] [Abstract][Full Text] [Related]
56. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
57. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
58. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor.
Rusthoven KE; Koshy M; Paulino AC
Cancer; 2004 Dec; 101(11):2641-9. PubMed ID: 15517576
[TBL] [Abstract][Full Text] [Related]
59. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.
Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2013 May; 49(5):449-53. PubMed ID: 23321549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
